#1 Clinical Trials Search in Europe

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

4 1 1 1

What is this study about?

This study focuses on patients with Acute Myeloid Leukemia (AML) who still have measurable traces of cancer cells after initial chemotherapy or before stem cell transplantation. The study tests a combination treatment using two medications: venetoclax (taken as tablets by mouth) and azacitidine (given through injection under the skin or into a vein). This remaining trace amount of cancer cells is called Measurable Residual Disease (MRD).

The purpose of this research is to determine if the combination of venetoclax and azacitidine can eliminate these remaining cancer cells in AML patients. The treatment will be given in courses lasting up to 24 months. During the treatment, patients will receive venetoclax tablets daily (up to 400 mg per day) and azacitidine injections (75 mg per square meter of body surface).

The study includes two groups of patients: those who have a favorable type of AML and are not scheduled for stem cell transplantation, and those with other types of AML who are planned to receive a stem cell transplant. Regular tests will be performed to check if the cancer cells are still present in the bone marrow and blood during and after the treatment.

1 Initial treatment cycle

You will receive a combination of two medications: azacitidine and venetoclax

Azacitidine will be administered either through an intravenous (IV) line or as an injection under the skin

Venetoclax will be taken as film-coated tablets by mouth

The treatment will be organized in cycles

2 Monitoring period

Your blood cells and bone marrow will be regularly checked to measure the presence of remaining cancer cells (measurable residual disease or MRD)

Blood tests will be performed to monitor your liver and kidney function

The medical team will assess your general health status during each visit

3 Treatment continuation

Based on your response, you may receive between 2 to 4 courses of treatment

Each course will follow the same medication pattern as the initial cycle

Regular monitoring of your condition will continue throughout the treatment period

4 Follow-up period

After completing the treatment cycles, you will continue to be monitored for any changes in your condition

Regular checks will be performed to assess if the cancer remains under control

The follow-up period will continue according to the study protocol

Who Can Join the Study?

  • Must be at least 18 years old
  • Must have acute myeloid leukemia (AML) with either:
    – Persistent measurable residual disease (remaining cancer cells) or
    – Return of residual disease after initial chemotherapy
    – Or detectable disease before stem cell transplantation
  • Must have previously received at least one cycle of chemotherapy with drugs called cytarabine and anthracycline
  • Must have no signs of cancer spread to the brain or spinal cord
  • Must have good overall physical function (ECOG score of 2 or less)
  • Must have adequate kidney function (creatinine clearance of 30 mL/min or higher)
  • Must have adequate liver function with:
    – Liver enzymes (AST and ALT) no more than 3 times the normal limit
    – Bilirubin no more than 1.5 times the normal limit
  • Must be willing and able to sign an informed consent form
  • For men: Must use contraception during the study and for 3 months after the last dose
  • For women who can become pregnant: Must use two forms of contraception or practice complete abstinence:
    – For 28 days before starting treatment
    – Throughout the entire treatment
    – For 6 months after the last dose

Who Cannot Join the Study?

  • Age below 18 years or above 70 years
  • Previous treatment with venetoclax (a type of cancer medication)
  • Current active infection that requires intravenous antibiotics
  • Severe heart problems, including uncontrolled heart failure or recent heart attack
  • Severe liver problems (liver function tests more than 3 times the normal limit)
  • Severe kidney problems (requiring dialysis)
  • Pregnancy or breastfeeding
  • Active secondary cancer (another type of cancer present at the same time)
  • Participation in another clinical trial within the last 30 days
  • Mental conditions that prevent understanding of the study requirements
  • Known allergic reactions to study medications
  • Uncontrolled high blood pressure
  • History of significant bleeding in the last 6 months
  • Active central nervous system involvement of leukemia
  • Inability to take oral medications

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hospital General Universitario Gregorio Maranon Madrid Spain
Hospital Del Mar Barcelona Spain
Hospital Universitari Joan XXIII De Tarragona Tarragona Spain
Hospital Clinic De Barcelona Barcelona Spain
Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida Lleida Spain
Hospital Son Llatzer Palma Spain
Fundacio Assistencial De Mutua De Terrassa Fpc Terrassa Spain
Servei De Salut De Les Illes Balears Palma Spain
Iyuwbmth Cpsdzl Dpbhoyhpzteepsace L'hospitalet De Llobregat Spain
Hanrpktv Dv Lj Sepdc Coll I Scoh Pbf Barcelona Spain
Hgpqopzs Vjhz dwwhcyfi Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not recruiting
15.07.2024

Trial locations

Investigated drugs:

Venetoclax is a medication used to treat acute myeloid leukemia (AML). It works by blocking a protein that helps cancer cells survive. This medication helps eliminate remaining cancer cells that may not be visible through regular tests but can be detected through special testing (known as measurable residual disease or MRD).

Azacitidine is a chemotherapy medication that works by helping to correct the function of abnormal cells in bone marrow. It is used in combination with venetoclax to treat acute myeloid leukemia. This medication helps to stop cancer cells from growing and may help destroy them.

The combination of these two medications is used before stem cell transplantation to help eliminate any remaining cancer cells and improve treatment outcomes for patients with acute myeloid leukemia.

Investigated diseases:

Acute Myeloid Leukemia (AML) – A type of blood and bone marrow cancer that affects the production of blood cells. The disease develops when the bone marrow produces abnormal white blood cells, known as myeloid cells, which grow rapidly and interfere with normal blood cell production. These abnormal cells accumulate in the bone marrow and blood, reducing the body’s ability to produce healthy blood cells. The condition can progress quickly, affecting the production of red blood cells and platelets. Measurable residual disease (MRD) refers to the presence of small numbers of leukemia cells that may remain after treatment.

Trial ID:
2024-510648-29-00
Protocol code:
CETLAM-LMA-AC-202401
Trial Phase:
Therapeutic use (Phase IV)

Other Trials to Consider

  • Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7